Cigliola V, Thorel F, Chera S, Herrera P L
Department of Genetic Medicine and Development, Faculty of Medicine, Institute of Genetics and Genomics in Geneva (iGE3), and Centre facultaire du diabète, University of Geneva, Geneva, Switzerland.
Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway.
Diabetes Obes Metab. 2016 Sep;18 Suppl 1(Suppl 1):87-96. doi: 10.1111/dom.12726.
The different forms of diabetes mellitus differ in their pathogenesis but, ultimately, they are all characterized by progressive islet β-cell loss. Restoring the β-cell mass is therefore a major goal for future therapeutic approaches. The number of β-cells found at birth is determined by proliferation and differentiation of pancreatic progenitor cells, and it has been considered to remain mostly unchanged throughout adult life. Recent studies in mice have revealed an unexpected plasticity in islet endocrine cells in response to stress; under certain conditions, islet non-β-cells have the potential to reprogram into insulin producers, thus contributing to restore the β-cell mass. Here, we discuss the latest findings on pancreas and islet cell plasticity upon physiological, pathological and experimental conditions of stress. Understanding the mechanisms involved in cell reprogramming in these models will allow the development of new strategies for the treatment of diabetes, by exploiting the intrinsic regeneration capacity of the pancreas.
不同类型的糖尿病在发病机制上有所不同,但最终,它们都以胰岛β细胞进行性丧失为特征。因此,恢复β细胞数量是未来治疗方法的主要目标。出生时发现的β细胞数量由胰腺祖细胞的增殖和分化决定,并且一直被认为在成年期大部分时间保持不变。最近对小鼠的研究揭示了胰岛内分泌细胞在应激反应中出人意料的可塑性;在某些条件下,胰岛非β细胞有可能重编程为胰岛素产生细胞,从而有助于恢复β细胞数量。在这里,我们讨论在生理、病理和实验应激条件下胰腺和胰岛细胞可塑性的最新发现。了解这些模型中细胞重编程所涉及的机制将有助于开发新的糖尿病治疗策略,即利用胰腺的内在再生能力。